Alto NeuroscienceANRO +6.88%12 EV-to-FCF is -11.27 as of Jun. 28, 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 336 Biotechnology companies, Alto Neuroscience ranks worse than 297618.75% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alto Neuroscience's Enterprise Value is $708.39 Mil.
Alto Neuroscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-62.86 Mil. Therefore, Alto Neuroscience's EV-to-FCF for today is -11.27.
The historical rank and industry rank for Alto Neuroscience's EV-to-FCF or its related term are showing as below:
ANRO'
s EV-to-FCF Range Over the Past 10 Years
Min: -11.27 Med: 0 Max: 0
Current: -11.27
ANRO's EV-to-FCF is ranked worse than 100% of 336
companies
in the Biotechnology industry
Industry Median: 14.7
vs ANRO: -11.27
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alto Neuroscience's PE Ratio (TTM) for today is calculated as:
Alto Neuroscience's share price for today is $27.04.
Alto Neuroscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.420.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alto Neuroscience EV-to-FCF Related Terms
Alto Neuroscience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Alto Neuroscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alto Neuroscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alto Neuroscience EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alto Neuroscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Alto Neuroscience's EV-to-FCF falls into.
Alto Neuroscience's current Enterprise Value is $708.39 Mil.
Alto Neuroscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-62.86 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alto Neuroscience (ANRO) has a EV-to-FCF of -11.27 as of Jun. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alto Neuroscience and its competitors. According to the industry distribution chart, Alto Neuroscience ranks #999999 out of 336 companies in the Biotechnology industry.
Is Alto Neuroscience's EV-to-FCF too high?
Alto Neuroscience's current EV-to-FCF is -11.27. Based on the distribution chart, Alto Neuroscience ranks #999999 out of 336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's EV-to-FCF compare to MRVI and BBOT?
According to the Biotechnology industry distribution chart, Alto Neuroscience ranks #999999 out of 336 companies for EV-to-FCF. This places Alto Neuroscience in the lower half of its industry. The industry median EV-to-FCF is 14.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.70, based on 336 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Alto Neuroscience and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alto Neuroscience's current EV-to-FCF is -11.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current EV-to-FCF of -11.27. The current EV-to-FCF is -11.27. Alto Neuroscience's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current EV-to-FCF is -11.27 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score
Get the complete analysis for ANRO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANRO has been successfully added to your 
